CNS Pharmaceuticals, Inc. (CNSP)
After hours:
| Previous Close | 0.2211 |
| Open | 0.2190 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2014 - 0.2190 |
| 52 Week Range | 0.1900 - 2.9800 |
| Volume | |
| Avg. Volume | 252,098 |
| Market Cap | 2.148M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.0000 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRECNS Pharmaceuticals to Present at the LSX World Congress 2024
Presentation on Monday, April 29th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...
- ACCESSWIRE
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing ...
- ACCESSWIRE
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM study Berubicin study enrollment completed; Topline data expected ...
